Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis
- PMID:29706404
- DOI: 10.1016/j.jjcc.2018.03.009
Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis
Abstract
Background: We evaluated the dose-dependent efficacy, safety, and all-cause mortality of non-vitamin K antagonist oral anticoagulants (NOACs) in "atrial fibrillation (AF) patients who were OAC-naïve," or "AF patients with prior-stroke history" with those who were known to be high-risk subgroups under OAC.
Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), five phase-III randomized trials comparing NOACs and warfarin in "OAC-naïve/OAC-experienced," or "with/without prior-stroke history" subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risk (RR) for stroke/systemic thromboembolism (SSTE), major bleeding, intracranial hemorrhage, and all-cause mortality.
Results: 1. In OAC-naïve patients, standard-dose NOACs showed superior efficacy and safety with lower mortality [RR 0.90 (0.84-0.97), p=0.008, I2=0%] compared to warfarin. 2. For OAC-experienced patients, low-dose NOACs showed equivalent efficacy but reduced risk of major bleeding [RR 0.61 (0.40-0.91), p=0.02, I2=89%], and had lower all-cause mortality [RR 0.86 (0.75-0.99), p=0.04, I2=38%] compared to warfarin. 3. For patients with prior-stroke history, low-dose NOACs showed equivalent efficacy, but reduced risk of major bleeding [RR 0.58 (0.48-0.70), p<0.001, I2=0%] and all-cause mortality [RR 0.76 (0.66-0.88), p<0.001, I2=0%] compared to warfarin. 4. Among patients without prior-stroke history, standard-dose NOAC was superior to warfarin for both SSTE prevention [RR 0.78 (0.66-0.91), p=0.002, I2=43%] and all-cause mortality [RR 0.91 (0.85-0.97), p=0.004, I2=0%].
Conclusions: In conclusion, standard-dose NOAC showed lower all-cause mortality than warfarin in OAC-naïve patients with AF, and low-dose NOAC was better than warfarin among the patients with prior-stroke history in terms of all-cause mortality.
Keywords: Atrial fibrillation; Meta-analysis; Non-vitamin K antagonist oral anticoagulant; Oral anticoagulant-naïve; Previous stroke.
Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Similar articles
- Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.Kim IS, Kim HJ, Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN.Kim IS, et al.J Cardiol. 2019 Jun;73(6):515-521. doi: 10.1016/j.jjcc.2018.12.018. Epub 2019 Feb 13.J Cardiol. 2019.PMID:30770140
- Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis.Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, Pak HN.Kim IS, et al.J Cardiol. 2018 Aug;72(2):105-112. doi: 10.1016/j.jjcc.2018.01.015. Epub 2018 Mar 5.J Cardiol. 2018.PMID:29519547
- Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M.Pan KL, et al.J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835.J Am Heart Assoc. 2017.PMID:28720644Free PMC article.Review.
- Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP.Wang KL, et al.Eur Heart J. 2019 May 14;40(19):1492-1500. doi: 10.1093/eurheartj/ehy802.Eur Heart J. 2019.PMID:30590440
- Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis.Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS, Lip GYH.Bai Y, et al.Age Ageing. 2018 Jan 1;47(1):9-17. doi: 10.1093/ageing/afx103.Age Ageing. 2018.PMID:28985259Review.
Cited by
- Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation.Park J, Lee SR, Choi EK, Kwon S, Jung JH, Han KD, Cha MJ, Ko SB, Oh S, Lip GYH.Park J, et al.J Clin Med. 2019 Dec 17;8(12):2228. doi: 10.3390/jcm8122228.J Clin Med. 2019.PMID:31861095Free PMC article.
- Left Atrial Appendage Closure Yields Favorable Cardio- and Cerebrovascular Outcomes in Patients With Non-valvular Atrial Fibrillation and Prior Stroke.Zhao M, Zhao M, Hou CR, Post F, Herold N, Walsleben J, Meng Z, Yu J.Zhao M, et al.Front Neurol. 2022 Jan 10;12:784557. doi: 10.3389/fneur.2021.784557. eCollection 2021.Front Neurol. 2022.PMID:35082747Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical